Vinorelbine, cyclophosphamide and 5-FU effects on the circulating and intratumoural landscape of immune cells improve anti-PD-L1 efficacy in preclinical models of breast cancer and lymphoma

Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas

(2018) Maud Toulmonde et al.   JAMA Oncology

Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer

(2017) Nicholas A. Taylor et al.   JOURNAL OF CLINICAL INVESTIGATION

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

Combined immune checkpoint blockade as a therapeutic strategy for BRCA1 -mutated breast cancer

(2017) Emma Nolan et al.   Science Translational Medicine

In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy

(2017) Sean P. Arlauckas et al.   Science Translational Medicine

Reversing T-cell Dysfunction and Exhaustion in Cancer

(2016) H. M. Zarour   CLINICAL CANCER RESEARCH

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

(2016) P. S. Hegde et al.   CLINICAL CANCER RESEARCH

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

(2016) Christina Pfirschke et al.   IMMUNITY

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells

(2016) Olivier De Henau et al.   NATURE

Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect

(2016) Guido Bocci et al.   Nature Reviews Clinical Oncology

Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway

(2016) Vassiliki A. Boussiotis   NEW ENGLAND JOURNAL OF MEDICINE

Anti-PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

(2016) D. Mathios et al.   Science Translational Medicine

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards

(2016) Vincenzo Bronte et al.   Nature Communications

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

(2015) Lorenzo Galluzzi et al.   CANCER CELL

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

(2015) Idit Sagiv-Barfi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+T-cell responses and immune memory

(2015) Junjie Wu et al.   OncoImmunology

Chemotherapy-induced myeloid suppressor cells and antitumor immunity: The Janus face of chemotherapy in immunomodulation

(2014) Zhi-Chun Ding et al.   OncoImmunology

Complementary Populations of Human Adipose CD34+ Progenitor Cells Promote Growth, Angiogenesis, and Metastasis of Breast Cancer

(2013) S. Orecchioni et al.   CANCER RESEARCH

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of conventional therapeutic interventions on the number and function of regulatory T cells

(2013) Mario Roselli et al.   OncoImmunology

The White Adipose Tissue Used in Lipotransfer Procedures Is a Rich Reservoir of CD34+ Progenitors Able to Promote Cancer Progression

(2011) I. Martin-Padura et al.   CANCER RESEARCH

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

Metronomic chemotherapy: new rationale for new directions

(2010) Eddy Pasquier et al.   Nature Reviews Clinical Oncology